Global Adeno-Associated Virus (AAV) Gene Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Adeno-Associated Virus (AAV) Gene Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 112

Published Date: 08 Jun 2023

Category: Service & Software

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Related Reports
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

According to our (Global Info Research) latest study, the global Adeno-Associated Virus (AAV) Gene Therapy market size was valued at USD 1684.4 million in 2022 and is forecast to a readjusted size of USD 2966.6 million by 2029 with a CAGR of 8.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Adeno-Associated Virus (AAV) Gene Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Adeno-Associated Virus (AAV) Gene Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Adeno-Associated Virus (AAV) Gene Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Adeno-Associated Virus (AAV) Gene Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Adeno-Associated Virus (AAV) Gene Therapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adeno-Associated Virus (AAV) Gene Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adeno-Associated Virus (AAV) Gene Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Creative Biolabs, Affinia Therapeutics, Spark Therapeutics, AGC Biologics and StrideBio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Adeno-Associated Virus (AAV) Gene Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Luxturna
Zolgensma
Others

Market segment by Application
Central Nervous System Diseases
Ocular Diseases
Liver-directed Diseases
Other Hereditary Diseases

Market segment by players, this report covers
Creative Biolabs
Affinia Therapeutics
Spark Therapeutics
AGC Biologics
StrideBio
SIRION Biotech
Neurophth Biotechnology
Belief BioMed
BiBo Biopharma Engineering Co., LTD.
Beihai Kangcheng
PackGene Biotech
Sarepta Therapeutics
Carbon BioSciences
Kelonia Therapeutics
Roche
Remedium Bio

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Adeno-Associated Virus (AAV) Gene Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Adeno-Associated Virus (AAV) Gene Therapy, with revenue, gross margin and global market share of Adeno-Associated Virus (AAV) Gene Therapy from 2018 to 2023.
Chapter 3, the Adeno-Associated Virus (AAV) Gene Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Adeno-Associated Virus (AAV) Gene Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Adeno-Associated Virus (AAV) Gene Therapy.
Chapter 13, to describe Adeno-Associated Virus (AAV) Gene Therapy research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Adeno-Associated Virus (AAV) Gene Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Adeno-Associated Virus (AAV) Gene Therapy by Type
1.3.1 Overview: Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type in 2022
1.3.3 Luxturna
1.3.4 Zolgensma
1.3.5 Others
1.4 Global Adeno-Associated Virus (AAV) Gene Therapy Market by Application
1.4.1 Overview: Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Central Nervous System Diseases
1.4.3 Ocular Diseases
1.4.4 Liver-directed Diseases
1.4.5 Other Hereditary Diseases
1.5 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size & Forecast
1.6 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast by Region
1.6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region, (2018-2029)
1.6.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.4 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.6 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)

2 Company Profiles
2.1 Creative Biolabs
2.1.1 Creative Biolabs Details
2.1.2 Creative Biolabs Major Business
2.1.3 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.1.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Creative Biolabs Recent Developments and Future Plans
2.2 Affinia Therapeutics
2.2.1 Affinia Therapeutics Details
2.2.2 Affinia Therapeutics Major Business
2.2.3 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.2.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Affinia Therapeutics Recent Developments and Future Plans
2.3 Spark Therapeutics
2.3.1 Spark Therapeutics Details
2.3.2 Spark Therapeutics Major Business
2.3.3 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.3.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Spark Therapeutics Recent Developments and Future Plans
2.4 AGC Biologics
2.4.1 AGC Biologics Details
2.4.2 AGC Biologics Major Business
2.4.3 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.4.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 AGC Biologics Recent Developments and Future Plans
2.5 StrideBio
2.5.1 StrideBio Details
2.5.2 StrideBio Major Business
2.5.3 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.5.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 StrideBio Recent Developments and Future Plans
2.6 SIRION Biotech
2.6.1 SIRION Biotech Details
2.6.2 SIRION Biotech Major Business
2.6.3 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.6.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 SIRION Biotech Recent Developments and Future Plans
2.7 Neurophth Biotechnology
2.7.1 Neurophth Biotechnology Details
2.7.2 Neurophth Biotechnology Major Business
2.7.3 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.7.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Neurophth Biotechnology Recent Developments and Future Plans
2.8 Belief BioMed
2.8.1 Belief BioMed Details
2.8.2 Belief BioMed Major Business
2.8.3 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.8.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Belief BioMed Recent Developments and Future Plans
2.9 BiBo Biopharma Engineering Co., LTD.
2.9.1 BiBo Biopharma Engineering Co., LTD. Details
2.9.2 BiBo Biopharma Engineering Co., LTD. Major Business
2.9.3 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.9.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 BiBo Biopharma Engineering Co., LTD. Recent Developments and Future Plans
2.10 Beihai Kangcheng
2.10.1 Beihai Kangcheng Details
2.10.2 Beihai Kangcheng Major Business
2.10.3 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.10.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Beihai Kangcheng Recent Developments and Future Plans
2.11 PackGene Biotech
2.11.1 PackGene Biotech Details
2.11.2 PackGene Biotech Major Business
2.11.3 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.11.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 PackGene Biotech Recent Developments and Future Plans
2.12 Sarepta Therapeutics
2.12.1 Sarepta Therapeutics Details
2.12.2 Sarepta Therapeutics Major Business
2.12.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.12.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Sarepta Therapeutics Recent Developments and Future Plans
2.13 Carbon BioSciences
2.13.1 Carbon BioSciences Details
2.13.2 Carbon BioSciences Major Business
2.13.3 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.13.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Carbon BioSciences Recent Developments and Future Plans
2.14 Kelonia Therapeutics
2.14.1 Kelonia Therapeutics Details
2.14.2 Kelonia Therapeutics Major Business
2.14.3 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.14.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Kelonia Therapeutics Recent Developments and Future Plans
2.15 Roche
2.15.1 Roche Details
2.15.2 Roche Major Business
2.15.3 Roche Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.15.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Roche Recent Developments and Future Plans
2.16 Remedium Bio
2.16.1 Remedium Bio Details
2.16.2 Remedium Bio Major Business
2.16.3 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.16.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Remedium Bio Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Adeno-Associated Virus (AAV) Gene Therapy by Company Revenue
3.2.2 Top 3 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share in 2022
3.2.3 Top 6 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share in 2022
3.3 Adeno-Associated Virus (AAV) Gene Therapy Market: Overall Company Footprint Analysis
3.3.1 Adeno-Associated Virus (AAV) Gene Therapy Market: Region Footprint
3.3.2 Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Type Footprint
3.3.3 Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
4.1 Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
5.1 Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Forecast by Application (2024-2029)

6 North America
6.1 North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
6.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
6.3.1 North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
6.3.2 United States Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
6.3.3 Canada Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
7.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
7.3.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
7.3.2 Germany Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.3 France Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.5 Russia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.6 Italy Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

8 Asia-Pacific
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region
8.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2018-2029)
8.3.2 China Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.3 Japan Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.5 India Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.7 Australia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

9 South America
9.1 South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
9.2 South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
9.3 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
9.3.1 South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

10 Middle East & Africa
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
10.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
10.3.4 UAE Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

11 Market Dynamics
11.1 Adeno-Associated Virus (AAV) Gene Therapy Market Drivers
11.2 Adeno-Associated Virus (AAV) Gene Therapy Market Restraints
11.3 Adeno-Associated Virus (AAV) Gene Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
12.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Chain
12.2 Adeno-Associated Virus (AAV) Gene Therapy Upstream Analysis
12.3 Adeno-Associated Virus (AAV) Gene Therapy Midstream Analysis
12.4 Adeno-Associated Virus (AAV) Gene Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Creative Biolabs Company Information, Head Office, and Major Competitors
Table 6. Creative Biolabs Major Business
Table 7. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 8. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Creative Biolabs Recent Developments and Future Plans
Table 10. Affinia Therapeutics Company Information, Head Office, and Major Competitors
Table 11. Affinia Therapeutics Major Business
Table 12. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 13. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Affinia Therapeutics Recent Developments and Future Plans
Table 15. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 16. Spark Therapeutics Major Business
Table 17. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 18. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Spark Therapeutics Recent Developments and Future Plans
Table 20. AGC Biologics Company Information, Head Office, and Major Competitors
Table 21. AGC Biologics Major Business
Table 22. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 23. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. AGC Biologics Recent Developments and Future Plans
Table 25. StrideBio Company Information, Head Office, and Major Competitors
Table 26. StrideBio Major Business
Table 27. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 28. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. StrideBio Recent Developments and Future Plans
Table 30. SIRION Biotech Company Information, Head Office, and Major Competitors
Table 31. SIRION Biotech Major Business
Table 32. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 33. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. SIRION Biotech Recent Developments and Future Plans
Table 35. Neurophth Biotechnology Company Information, Head Office, and Major Competitors
Table 36. Neurophth Biotechnology Major Business
Table 37. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 38. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Neurophth Biotechnology Recent Developments and Future Plans
Table 40. Belief BioMed Company Information, Head Office, and Major Competitors
Table 41. Belief BioMed Major Business
Table 42. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 43. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Belief BioMed Recent Developments and Future Plans
Table 45. BiBo Biopharma Engineering Co., LTD. Company Information, Head Office, and Major Competitors
Table 46. BiBo Biopharma Engineering Co., LTD. Major Business
Table 47. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 48. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. BiBo Biopharma Engineering Co., LTD. Recent Developments and Future Plans
Table 50. Beihai Kangcheng Company Information, Head Office, and Major Competitors
Table 51. Beihai Kangcheng Major Business
Table 52. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 53. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Beihai Kangcheng Recent Developments and Future Plans
Table 55. PackGene Biotech Company Information, Head Office, and Major Competitors
Table 56. PackGene Biotech Major Business
Table 57. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 58. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. PackGene Biotech Recent Developments and Future Plans
Table 60. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 61. Sarepta Therapeutics Major Business
Table 62. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 63. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Sarepta Therapeutics Recent Developments and Future Plans
Table 65. Carbon BioSciences Company Information, Head Office, and Major Competitors
Table 66. Carbon BioSciences Major Business
Table 67. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 68. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Carbon BioSciences Recent Developments and Future Plans
Table 70. Kelonia Therapeutics Company Information, Head Office, and Major Competitors
Table 71. Kelonia Therapeutics Major Business
Table 72. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 73. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Kelonia Therapeutics Recent Developments and Future Plans
Table 75. Roche Company Information, Head Office, and Major Competitors
Table 76. Roche Major Business
Table 77. Roche Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 78. Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Roche Recent Developments and Future Plans
Table 80. Remedium Bio Company Information, Head Office, and Major Competitors
Table 81. Remedium Bio Major Business
Table 82. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 83. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Remedium Bio Recent Developments and Future Plans
Table 85. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million) by Players (2018-2023)
Table 86. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Players (2018-2023)
Table 87. Breakdown of Adeno-Associated Virus (AAV) Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Adeno-Associated Virus (AAV) Gene Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 89. Head Office of Key Adeno-Associated Virus (AAV) Gene Therapy Players
Table 90. Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Type Footprint
Table 91. Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Application Footprint
Table 92. Adeno-Associated Virus (AAV) Gene Therapy New Market Entrants and Barriers to Market Entry
Table 93. Adeno-Associated Virus (AAV) Gene Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (USD Million) by Type (2018-2023)
Table 95. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Share by Type (2018-2023)
Table 96. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Forecast by Type (2024-2029)
Table 97. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023)
Table 98. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Forecast by Application (2024-2029)
Table 99. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 100. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 101. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 102. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 103. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 104. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 105. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 108. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 109. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 112. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 113. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 114. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 115. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 116. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 117. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 118. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 119. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 120. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 121. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 122. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 124. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 125. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 126. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 127. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 128. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 129. Adeno-Associated Virus (AAV) Gene Therapy Raw Material
Table 130. Key Suppliers of Adeno-Associated Virus (AAV) Gene Therapy Raw Materials
List of Figures
Figure 1. Adeno-Associated Virus (AAV) Gene Therapy Picture
Figure 2. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type in 2022
Figure 4. Luxturna
Figure 5. Zolgensma
Figure 6. Others
Figure 7. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application in 2022
Figure 9. Central Nervous System Diseases Picture
Figure 10. Ocular Diseases Picture
Figure 11. Liver-directed Diseases Picture
Figure 12. Other Hereditary Diseases Picture
Figure 13. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Region in 2022
Figure 18. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Players in 2022
Figure 24. Adeno-Associated Virus (AAV) Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Adeno-Associated Virus (AAV) Gene Therapy Market Share in 2022
Figure 26. Global Top 6 Players Adeno-Associated Virus (AAV) Gene Therapy Market Share in 2022
Figure 27. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Share by Type (2018-2023)
Figure 28. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Type (2024-2029)
Figure 29. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Share by Application (2018-2023)
Figure 30. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Application (2024-2029)
Figure 31. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 41. France Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Region (2018-2029)
Figure 48. China Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 51. India Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 65. Adeno-Associated Virus (AAV) Gene Therapy Market Drivers
Figure 66. Adeno-Associated Virus (AAV) Gene Therapy Market Restraints
Figure 67. Adeno-Associated Virus (AAV) Gene Therapy Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Adeno-Associated Virus (AAV) Gene Therapy in 2022
Figure 70. Manufacturing Process Analysis of Adeno-Associated Virus (AAV) Gene Therapy
Figure 71. Adeno-Associated Virus (AAV) Gene Therapy Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Creative Biolabs
Affinia Therapeutics
Spark Therapeutics
AGC Biologics
StrideBio
SIRION Biotech
Neurophth Biotechnology
Belief BioMed
BiBo Biopharma Engineering Co., LTD.
Beihai Kangcheng
PackGene Biotech
Sarepta Therapeutics
Carbon BioSciences
Kelonia Therapeutics
Roche
Remedium Bio
shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Adeno-Associated Virus (AAV) Gene Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Adeno-Associated Virus (AAV) Gene Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 112

Published Date: 08 Jun 2023

Category: Service & Software

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

According to our (Global Info Research) latest study, the global Adeno-Associated Virus (AAV) Gene Therapy market size was valued at USD 1684.4 million in 2022 and is forecast to a readjusted size of USD 2966.6 million by 2029 with a CAGR of 8.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Adeno-Associated Virus (AAV) Gene Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Adeno-Associated Virus (AAV) Gene Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Adeno-Associated Virus (AAV) Gene Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Adeno-Associated Virus (AAV) Gene Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Adeno-Associated Virus (AAV) Gene Therapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adeno-Associated Virus (AAV) Gene Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adeno-Associated Virus (AAV) Gene Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Creative Biolabs, Affinia Therapeutics, Spark Therapeutics, AGC Biologics and StrideBio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Adeno-Associated Virus (AAV) Gene Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Luxturna
Zolgensma
Others

Market segment by Application
Central Nervous System Diseases
Ocular Diseases
Liver-directed Diseases
Other Hereditary Diseases

Market segment by players, this report covers
Creative Biolabs
Affinia Therapeutics
Spark Therapeutics
AGC Biologics
StrideBio
SIRION Biotech
Neurophth Biotechnology
Belief BioMed
BiBo Biopharma Engineering Co., LTD.
Beihai Kangcheng
PackGene Biotech
Sarepta Therapeutics
Carbon BioSciences
Kelonia Therapeutics
Roche
Remedium Bio

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Adeno-Associated Virus (AAV) Gene Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Adeno-Associated Virus (AAV) Gene Therapy, with revenue, gross margin and global market share of Adeno-Associated Virus (AAV) Gene Therapy from 2018 to 2023.
Chapter 3, the Adeno-Associated Virus (AAV) Gene Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Adeno-Associated Virus (AAV) Gene Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Adeno-Associated Virus (AAV) Gene Therapy.
Chapter 13, to describe Adeno-Associated Virus (AAV) Gene Therapy research findings and conclusion.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Adeno-Associated Virus (AAV) Gene Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Adeno-Associated Virus (AAV) Gene Therapy by Type
1.3.1 Overview: Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type in 2022
1.3.3 Luxturna
1.3.4 Zolgensma
1.3.5 Others
1.4 Global Adeno-Associated Virus (AAV) Gene Therapy Market by Application
1.4.1 Overview: Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Central Nervous System Diseases
1.4.3 Ocular Diseases
1.4.4 Liver-directed Diseases
1.4.5 Other Hereditary Diseases
1.5 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size & Forecast
1.6 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast by Region
1.6.1 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region, (2018-2029)
1.6.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.4 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.6 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size and Prospect (2018-2029)

2 Company Profiles
2.1 Creative Biolabs
2.1.1 Creative Biolabs Details
2.1.2 Creative Biolabs Major Business
2.1.3 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.1.4 Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Creative Biolabs Recent Developments and Future Plans
2.2 Affinia Therapeutics
2.2.1 Affinia Therapeutics Details
2.2.2 Affinia Therapeutics Major Business
2.2.3 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.2.4 Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Affinia Therapeutics Recent Developments and Future Plans
2.3 Spark Therapeutics
2.3.1 Spark Therapeutics Details
2.3.2 Spark Therapeutics Major Business
2.3.3 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.3.4 Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Spark Therapeutics Recent Developments and Future Plans
2.4 AGC Biologics
2.4.1 AGC Biologics Details
2.4.2 AGC Biologics Major Business
2.4.3 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.4.4 AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 AGC Biologics Recent Developments and Future Plans
2.5 StrideBio
2.5.1 StrideBio Details
2.5.2 StrideBio Major Business
2.5.3 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.5.4 StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 StrideBio Recent Developments and Future Plans
2.6 SIRION Biotech
2.6.1 SIRION Biotech Details
2.6.2 SIRION Biotech Major Business
2.6.3 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.6.4 SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 SIRION Biotech Recent Developments and Future Plans
2.7 Neurophth Biotechnology
2.7.1 Neurophth Biotechnology Details
2.7.2 Neurophth Biotechnology Major Business
2.7.3 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.7.4 Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Neurophth Biotechnology Recent Developments and Future Plans
2.8 Belief BioMed
2.8.1 Belief BioMed Details
2.8.2 Belief BioMed Major Business
2.8.3 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.8.4 Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Belief BioMed Recent Developments and Future Plans
2.9 BiBo Biopharma Engineering Co., LTD.
2.9.1 BiBo Biopharma Engineering Co., LTD. Details
2.9.2 BiBo Biopharma Engineering Co., LTD. Major Business
2.9.3 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.9.4 BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 BiBo Biopharma Engineering Co., LTD. Recent Developments and Future Plans
2.10 Beihai Kangcheng
2.10.1 Beihai Kangcheng Details
2.10.2 Beihai Kangcheng Major Business
2.10.3 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.10.4 Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Beihai Kangcheng Recent Developments and Future Plans
2.11 PackGene Biotech
2.11.1 PackGene Biotech Details
2.11.2 PackGene Biotech Major Business
2.11.3 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.11.4 PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 PackGene Biotech Recent Developments and Future Plans
2.12 Sarepta Therapeutics
2.12.1 Sarepta Therapeutics Details
2.12.2 Sarepta Therapeutics Major Business
2.12.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.12.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Sarepta Therapeutics Recent Developments and Future Plans
2.13 Carbon BioSciences
2.13.1 Carbon BioSciences Details
2.13.2 Carbon BioSciences Major Business
2.13.3 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.13.4 Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Carbon BioSciences Recent Developments and Future Plans
2.14 Kelonia Therapeutics
2.14.1 Kelonia Therapeutics Details
2.14.2 Kelonia Therapeutics Major Business
2.14.3 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.14.4 Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Kelonia Therapeutics Recent Developments and Future Plans
2.15 Roche
2.15.1 Roche Details
2.15.2 Roche Major Business
2.15.3 Roche Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.15.4 Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Roche Recent Developments and Future Plans
2.16 Remedium Bio
2.16.1 Remedium Bio Details
2.16.2 Remedium Bio Major Business
2.16.3 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
2.16.4 Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Remedium Bio Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Adeno-Associated Virus (AAV) Gene Therapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Adeno-Associated Virus (AAV) Gene Therapy by Company Revenue
3.2.2 Top 3 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share in 2022
3.2.3 Top 6 Adeno-Associated Virus (AAV) Gene Therapy Players Market Share in 2022
3.3 Adeno-Associated Virus (AAV) Gene Therapy Market: Overall Company Footprint Analysis
3.3.1 Adeno-Associated Virus (AAV) Gene Therapy Market: Region Footprint
3.3.2 Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Type Footprint
3.3.3 Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
4.1 Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
5.1 Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Adeno-Associated Virus (AAV) Gene Therapy Market Forecast by Application (2024-2029)

6 North America
6.1 North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
6.2 North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
6.3 North America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
6.3.1 North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
6.3.2 United States Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
6.3.3 Canada Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
7.2 Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
7.3 Europe Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
7.3.1 Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
7.3.2 Germany Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.3 France Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.5 Russia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
7.3.6 Italy Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

8 Asia-Pacific
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Market Size by Region
8.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2018-2029)
8.3.2 China Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.3 Japan Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.5 India Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
8.3.7 Australia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

9 South America
9.1 South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
9.2 South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
9.3 South America Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
9.3.1 South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

10 Middle East & Africa
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market Size by Country
10.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)
10.3.4 UAE Adeno-Associated Virus (AAV) Gene Therapy Market Size and Forecast (2018-2029)

11 Market Dynamics
11.1 Adeno-Associated Virus (AAV) Gene Therapy Market Drivers
11.2 Adeno-Associated Virus (AAV) Gene Therapy Market Restraints
11.3 Adeno-Associated Virus (AAV) Gene Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
12.1 Adeno-Associated Virus (AAV) Gene Therapy Industry Chain
12.2 Adeno-Associated Virus (AAV) Gene Therapy Upstream Analysis
12.3 Adeno-Associated Virus (AAV) Gene Therapy Midstream Analysis
12.4 Adeno-Associated Virus (AAV) Gene Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Creative Biolabs Company Information, Head Office, and Major Competitors
Table 6. Creative Biolabs Major Business
Table 7. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 8. Creative Biolabs Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Creative Biolabs Recent Developments and Future Plans
Table 10. Affinia Therapeutics Company Information, Head Office, and Major Competitors
Table 11. Affinia Therapeutics Major Business
Table 12. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 13. Affinia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Affinia Therapeutics Recent Developments and Future Plans
Table 15. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 16. Spark Therapeutics Major Business
Table 17. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 18. Spark Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Spark Therapeutics Recent Developments and Future Plans
Table 20. AGC Biologics Company Information, Head Office, and Major Competitors
Table 21. AGC Biologics Major Business
Table 22. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 23. AGC Biologics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. AGC Biologics Recent Developments and Future Plans
Table 25. StrideBio Company Information, Head Office, and Major Competitors
Table 26. StrideBio Major Business
Table 27. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 28. StrideBio Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. StrideBio Recent Developments and Future Plans
Table 30. SIRION Biotech Company Information, Head Office, and Major Competitors
Table 31. SIRION Biotech Major Business
Table 32. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 33. SIRION Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. SIRION Biotech Recent Developments and Future Plans
Table 35. Neurophth Biotechnology Company Information, Head Office, and Major Competitors
Table 36. Neurophth Biotechnology Major Business
Table 37. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 38. Neurophth Biotechnology Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Neurophth Biotechnology Recent Developments and Future Plans
Table 40. Belief BioMed Company Information, Head Office, and Major Competitors
Table 41. Belief BioMed Major Business
Table 42. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 43. Belief BioMed Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Belief BioMed Recent Developments and Future Plans
Table 45. BiBo Biopharma Engineering Co., LTD. Company Information, Head Office, and Major Competitors
Table 46. BiBo Biopharma Engineering Co., LTD. Major Business
Table 47. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 48. BiBo Biopharma Engineering Co., LTD. Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. BiBo Biopharma Engineering Co., LTD. Recent Developments and Future Plans
Table 50. Beihai Kangcheng Company Information, Head Office, and Major Competitors
Table 51. Beihai Kangcheng Major Business
Table 52. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 53. Beihai Kangcheng Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Beihai Kangcheng Recent Developments and Future Plans
Table 55. PackGene Biotech Company Information, Head Office, and Major Competitors
Table 56. PackGene Biotech Major Business
Table 57. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 58. PackGene Biotech Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. PackGene Biotech Recent Developments and Future Plans
Table 60. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 61. Sarepta Therapeutics Major Business
Table 62. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 63. Sarepta Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Sarepta Therapeutics Recent Developments and Future Plans
Table 65. Carbon BioSciences Company Information, Head Office, and Major Competitors
Table 66. Carbon BioSciences Major Business
Table 67. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 68. Carbon BioSciences Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Carbon BioSciences Recent Developments and Future Plans
Table 70. Kelonia Therapeutics Company Information, Head Office, and Major Competitors
Table 71. Kelonia Therapeutics Major Business
Table 72. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 73. Kelonia Therapeutics Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Kelonia Therapeutics Recent Developments and Future Plans
Table 75. Roche Company Information, Head Office, and Major Competitors
Table 76. Roche Major Business
Table 77. Roche Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 78. Roche Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Roche Recent Developments and Future Plans
Table 80. Remedium Bio Company Information, Head Office, and Major Competitors
Table 81. Remedium Bio Major Business
Table 82. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Product and Solutions
Table 83. Remedium Bio Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Remedium Bio Recent Developments and Future Plans
Table 85. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue (USD Million) by Players (2018-2023)
Table 86. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Players (2018-2023)
Table 87. Breakdown of Adeno-Associated Virus (AAV) Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Adeno-Associated Virus (AAV) Gene Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 89. Head Office of Key Adeno-Associated Virus (AAV) Gene Therapy Players
Table 90. Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Type Footprint
Table 91. Adeno-Associated Virus (AAV) Gene Therapy Market: Company Product Application Footprint
Table 92. Adeno-Associated Virus (AAV) Gene Therapy New Market Entrants and Barriers to Market Entry
Table 93. Adeno-Associated Virus (AAV) Gene Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (USD Million) by Type (2018-2023)
Table 95. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Share by Type (2018-2023)
Table 96. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Forecast by Type (2024-2029)
Table 97. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023)
Table 98. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Forecast by Application (2024-2029)
Table 99. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 100. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 101. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 102. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 103. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 104. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 105. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 108. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 109. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 112. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 113. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 114. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 115. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 116. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 117. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 118. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 119. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 120. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 121. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 122. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 124. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 125. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 126. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 127. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 128. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 129. Adeno-Associated Virus (AAV) Gene Therapy Raw Material
Table 130. Key Suppliers of Adeno-Associated Virus (AAV) Gene Therapy Raw Materials
List of Figures
Figure 1. Adeno-Associated Virus (AAV) Gene Therapy Picture
Figure 2. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type in 2022
Figure 4. Luxturna
Figure 5. Zolgensma
Figure 6. Others
Figure 7. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application in 2022
Figure 9. Central Nervous System Diseases Picture
Figure 10. Ocular Diseases Picture
Figure 11. Liver-directed Diseases Picture
Figure 12. Other Hereditary Diseases Picture
Figure 13. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Region in 2022
Figure 18. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Adeno-Associated Virus (AAV) Gene Therapy Revenue Share by Players in 2022
Figure 24. Adeno-Associated Virus (AAV) Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Adeno-Associated Virus (AAV) Gene Therapy Market Share in 2022
Figure 26. Global Top 6 Players Adeno-Associated Virus (AAV) Gene Therapy Market Share in 2022
Figure 27. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Share by Type (2018-2023)
Figure 28. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Type (2024-2029)
Figure 29. Global Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Share by Application (2018-2023)
Figure 30. Global Adeno-Associated Virus (AAV) Gene Therapy Market Share Forecast by Application (2024-2029)
Figure 31. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 41. France Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Region (2018-2029)
Figure 48. China Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 51. India Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Adeno-Associated Virus (AAV) Gene Therapy Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Adeno-Associated Virus (AAV) Gene Therapy Consumption Value (2018-2029) & (USD Million)
Figure 65. Adeno-Associated Virus (AAV) Gene Therapy Market Drivers
Figure 66. Adeno-Associated Virus (AAV) Gene Therapy Market Restraints
Figure 67. Adeno-Associated Virus (AAV) Gene Therapy Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Adeno-Associated Virus (AAV) Gene Therapy in 2022
Figure 70. Manufacturing Process Analysis of Adeno-Associated Virus (AAV) Gene Therapy
Figure 71. Adeno-Associated Virus (AAV) Gene Therapy Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

Creative Biolabs
Affinia Therapeutics
Spark Therapeutics
AGC Biologics
StrideBio
SIRION Biotech
Neurophth Biotechnology
Belief BioMed
BiBo Biopharma Engineering Co., LTD.
Beihai Kangcheng
PackGene Biotech
Sarepta Therapeutics
Carbon BioSciences
Kelonia Therapeutics
Roche
Remedium Bio
jiaGou

Add To Cart

gouMai

Buy Now